Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlos Bais

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Nature|December 8, 2007
Bv8 regulates myeloid-cell-dependent tumour angiogenesisFarbod Shojaei, Xiumin Wu, Cuiling Zhong, et al.
European Journal of Cancer (Oxford, England : 1990)|November 8, 2016
Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluationDavid Miles, David Cameron, Igor Bondarenko, et al.
Nature Communications|November 5, 2020
Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancerMélanie Desbois, Akshata R Udyavar, Lisa Ryner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2015
Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio TrialThomas Sandmann, Richard Bourgon, Josep Garcia, et al.
Nature Communications|May 9, 2025
Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancerXueping Qu, Habib Hamidi, Radia M Johnson, et al.
Cell|February 18, 2014
Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumorsDiego O Croci, Juan P Cerliani, Tomas Dalotto-Moreno, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2016
Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O<sup>6</sup>-Methylguanine-DNA Methyltransferase Biomarker AnalysesTimothy Cloughesy, Gaetano Finocchiaro, Cristóbal Belda-Iniesta, et al.
Nature Communications|September 18, 2022
ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancerRadia M Johnson, Xueping Qu, Chu-Fang Lin, et al.
Cell|April 8, 2010
PlGF blockade does not inhibit angiogenesis during primary tumor growthCarlos Bais, Xiumin Wu, Jenny Yao, et al.
Nature|June 17, 2021
ctDNA guiding adjuvant immunotherapy in urothelial carcinomaThomas Powles, Zoe June Assaf, Nicole Davarpanah, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Nature|December 8, 2007
Bv8 regulates myeloid-cell-dependent tumour angiogenesisFarbod Shojaei, Xiumin Wu, Cuiling Zhong, et al.
European Journal of Cancer (Oxford, England : 1990)|November 8, 2016
Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluationDavid Miles, David Cameron, Igor Bondarenko, et al.
Nature Communications|November 5, 2020
Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancerMélanie Desbois, Akshata R Udyavar, Lisa Ryner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2015
Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio TrialThomas Sandmann, Richard Bourgon, Josep Garcia, et al.
Nature Communications|May 9, 2025
Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancerXueping Qu, Habib Hamidi, Radia M Johnson, et al.
Cell|February 18, 2014
Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumorsDiego O Croci, Juan P Cerliani, Tomas Dalotto-Moreno, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2016
Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O<sup>6</sup>-Methylguanine-DNA Methyltransferase Biomarker AnalysesTimothy Cloughesy, Gaetano Finocchiaro, Cristóbal Belda-Iniesta, et al.
Nature Communications|September 18, 2022
ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancerRadia M Johnson, Xueping Qu, Chu-Fang Lin, et al.
Cell|April 8, 2010
PlGF blockade does not inhibit angiogenesis during primary tumor growthCarlos Bais, Xiumin Wu, Jenny Yao, et al.
Nature|June 17, 2021
ctDNA guiding adjuvant immunotherapy in urothelial carcinomaThomas Powles, Zoe June Assaf, Nicole Davarpanah, et al.
Pageof 3